Market based medicine development

• Sembragiline, a joint development project for Alzheimer's disease from Roche and Evotec, did not demonstrate cognitive benefit in treated patients with Alzheimer's disease (AD) after 52 weeks. 
• This is the second AD drug failure for Roche in the last two years, including gantenerumab, which failed late last year.
• Evotec is still dedicated to CNS R&D, and has more than 70 CNS-related products at various stages of development in their portfolio, according to Evotec CEO Werner Lanthaler. 

http://www.biopharmadive.com/news/another-roche-alzheimers-drug-disappoints/401788/